Novadaq Technologies Inc.
TSX : NDQ

Novadaq Technologies Inc.

February 28, 2007 08:57 ET

Novadaq Receives Japanese Patent for the SPY Intra-Operative Imaging System

TORONTO, ONTARIO--(Marketwire - Feb. 28, 2007) -

Attention Business Editors:

Novadaq® Technologies Inc. (TSX:NDQ), today announced a patent grant
in Japan for its SPY® Intra-operative Imaging System. The Japanese Patent,
3881550, assigned to the National Research Council of Canada and exclusively
licensed to Novadaq Technologies Inc. is titled "Method and Apparatus for
Performing Intra-operative Angiography."

The SPY System enables cardiac surgeons to clearly visualize the flow of
blood through grafts during bypass procedures. Protection for this core
imaging technology in Japan represents a major commercial breakthrough for
Novadaq. The Japanese patent reinforces Novadaq's global strategy to build a
strong portfolio of protection for its innovative technology products and
emerging pipeline and further strengthens Novadaq's position as the imaging
company of the operating room.

"We at NRC are delighted to see our technology spreading around the world
to ensure the functionality of cardiac bypasses," said Dr. Ian C.P. Smith,
Director General, Institute for Biodiagnostics, National Research Council
Canada. "Our partnership with Novadaq is a source of great pride to us".

About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
imaging devices for use in the operating room. Novadaq's proprietary imaging
platform can be used to visualize blood vessels, nerves and the lymphatic
system during surgical procedures. Novadaq's SPY Intra-operative Imaging
System, commercially available worldwide, enables cardiac surgeons to visually
assess coronary vasculature and bypass graft functionality during the course
of open-heart surgery. Novadaq's OPTTX System which received CE Mark approval
in November 2006, is aimed at the diagnosis, evaluation and treatment of wet
Age-related Macular Degeneration (AMD) by using the same core imaging
technology that is used in the SPY System. The HELIOS™ System, which
received FDA clearance in January 2007, is the first fluorescent imaging
system available for use during plastic reconstructive surgery allowing
surgeons to evaluate pre- and intra-operative blood flow, as well as
post-surgery perfusion. Novadaq's LUNA™ system is designed to enable
surgeons to visualize nerve bundles during the course of urological and
neurological procedures. LUNA has been granted a license for use by Health
Canada. For more information, please visit the company's website at
www.novadaq.com.

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

Contact Information